Immunotherapy of melanoma: efficacy and mode of action (Q38682131)

5 September 2017

Immunotherapy of melanoma: efficacy and mode of action (English)

1 reference

5 September 2017

1 reference

Thomas Wieder

1

1 reference

5 September 2017

Ellen Brenner

series ordinal

2

1 reference

5 September 2017

Heidi Braumüller

series ordinal

3

1 reference

5 September 2017

Martin Röcken

series ordinal

4

1 reference

5 September 2017

1 January 2016

1 reference

5 September 2017

1 reference

5 September 2017

14

1 reference

5 September 2017

1

1 reference

5 September 2017

28-37

1 reference

Quantitative measurement of melanoma spread in sentinel lymph nodes and survival

5 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Diagnosis and treatment of cutaneous melanoma: state of the art 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

T-helper-1-cell cytokines drive cancer into senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Heterogeneity of T-cell clones infiltrating primary malignant melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Rethinking the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

The kiss of death: promises and failures of death receptors and ligands in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Cutaneous innate immune sensing of Toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

T cell-mediated help against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Inside and out: the activities of senescence in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

A change of strategy in the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Early tumor dissemination, but late metastasis: insights into tumor dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Changing T-cell enigma: cancer killing or cancer control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

The Role of Public-Sector Research in the Discovery of Drugs and Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

The $2.6 billion pill--methodologic and policy considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

High response rate after intratumoral treatment with interleukin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.110_12819

21 January 2018

Identifiers

DOI

10.1111/DDG.110_12819

1 reference

5 September 2017

1 reference